Literature DB >> 16179867

Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi.

Thilo Papp1, Holger Schipper, Krishan Kumar, Dietmar Schiffmann, Regina Zimmermann.   

Abstract

Eighteen congenital melanocytic naevi (CMN) from 17 patients and 18 dysplastic melanocytic naevi (DMN) from 18 patients were screened for mutations in the BRAF oncogene (present study) and the N-ras oncogene (in the course of two foregoing studies) by single-strand conformational polymorphism (SSCP)/sequencing analysis. BRAF mutations were demonstrated in both types of lesion. As a whole, 17 of 18 CMN (94.4%) and five of 18 DMN (27.7%) harboured either BRAF or N-ras mutations. As the BRAF oncogene is frequently found to be mutated in human cutaneous melanomas, it may constitute a risk factor for melanoma formation within CMN and DMN.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179867     DOI: 10.1097/00008390-200510000-00008

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  15 in total

1.  NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.

Authors:  Christelle Charbel; Romain H Fontaine; Gabriel G Malouf; Arnaud Picard; Natacha Kadlub; Nizar El-Murr; Alexandre How-Kit; Xiaoping Su; Aurore Coulomb-L'Hermine; Jorg Tost; Samia Mourah; Selim Aractingi; Sarah Guégan
Journal:  J Invest Dermatol       Date:  2013-10-15       Impact factor: 8.551

2.  Clonogenic cell subpopulations maintain congenital melanocytic nevi.

Authors:  Christelle Charbel; Romain H Fontaine; Natacha Kadlub; Aurore Coulomb-L'Hermine; Thomas Rouillé; Alexandre How-Kit; Philippe Moguelet; Jorg Tost; Arnaud Picard; Selim Aractingi; Sarah Guégan
Journal:  J Invest Dermatol       Date:  2014-10-13       Impact factor: 8.551

3.  The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

4.  Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.

Authors:  Tatsuhiro Shibata; Akiko Kokubu; Masashi Miyamoto; Yuko Sasajima; Naoya Yamazaki
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 5.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

6.  Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma.

Authors:  Brozyna Anna; Zbytek Blazej; Granese Jacqueline; Carlson J Andrew; Ross Jeffrey; Slominski Andrzej
Journal:  Expert Rev Dermatol       Date:  2007

Review 7.  Genetics of melanocytic nevi.

Authors:  Mi Ryung Roh; Philip Eliades; Sameer Gupta; Hensin Tsao
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

Review 8.  Biologically distinct subsets of nevi.

Authors:  Tova Rogers; Maria L Marino; Patricia Raciti; Manu Jain; Klaus J Busam; Michael A Marchetti; Ashfaq A Marghoob
Journal:  G Ital Dermatol Venereol       Date:  2016-04-27       Impact factor: 2.011

9.  Molecular nevogenesis.

Authors:  Andrew L Ross; Margaret I Sanchez; James M Grichnik
Journal:  Dermatol Res Pract       Date:  2011-04-06

10.  Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.

Authors:  Veronica A Kinsler; Anna C Thomas; Miho Ishida; Neil W Bulstrode; Sam Loughlin; Sandra Hing; Jane Chalker; Kathryn McKenzie; Sayeda Abu-Amero; Olga Slater; Estelle Chanudet; Rodger Palmer; Deborah Morrogh; Philip Stanier; Eugene Healy; Neil J Sebire; Gudrun E Moore
Journal:  J Invest Dermatol       Date:  2013-02-07       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.